Product Information
THEOPHYLLINE ER 400 MG TABLET is a generic product labeled by Rhodes Pharmaceuticals L.P., priced at $0.9953 per EA under NDC 42858070101. Its NADAC has been published 667 times since Nov 28, 2013.
FDA first approved this application on Sep 1, 1982. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Theophylline market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
400 mg/1
Manufacturer
Rhodes Pharmaceuticals L.P.NDC
42858070101
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
THEOPHYLLINE ANHYDROUSApproval Type
Generic (ANDA)
FDA Application
ANDA040086FDA Approved
9/1/1982
TE Code
AB
On Market Since
2/2/2012
Pharmacological Classes
Price Statistics
The NADAC for THEOPHYLLINE ER 400 MG TABLET has been published 667 times since Nov 28, 2013, and over the history we have for it it has risen 9.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.9953 per EA |
|---|---|
| All-time high | $1.0435 (Feb 12, 2014) |
| All-time low | $0.4646 (Nov 22, 2023) |
| 52-week high | $1.0376 |
| 52-week low | $0.8345 |
| Median price | $0.8260 |
| Average price | $0.8101 |
| Largest weekly change | +49.2% (Jan 17, 2024) |
| Weeks tracked | 667 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rhodes Pharmaceuticals L.P. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Theophylline market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Methylxanthine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of THEOPHYLLINE ER 400 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for THEOPHYLLINE ER 400 MG TABLET, manufactured by Rhodes Pharmaceuticals L.P., is $0.9953 per EA (NDC 42858070101), effective Sep 30, 2026.
How has the price of THEOPHYLLINE ER 400 MG TABLET changed over time?
Over the history we have for it, the NADAC for THEOPHYLLINE ER 400 MG TABLET has risen 9.2%. It has been tracked across 667 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for THEOPHYLLINE ER 400 MG TABLET?
Since Nov 28, 2013, the NADAC for THEOPHYLLINE ER 400 MG TABLET has ranged from a low of $0.4646 (Nov 22, 2023) to a high of $1.0435 (Feb 12, 2014), with a median of $0.8260 per EA.
Are there cheaper alternatives to THEOPHYLLINE ER 400 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as THEOPHYLLINE ER 400 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures THEOPHYLLINE ER 400 MG TABLET?
THEOPHYLLINE ER 400 MG TABLET (NDC 42858070101) is labeled by Rhodes Pharmaceuticals L.P., and CMS classifies it as a generic product.